Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,440 | 2,680 | 21:44 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 51 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
26.09. | Crossject announces its eligibility for France's PEA-PME investment scheme | 1 | GlobeNewswire (USA) | ||
23.09. | Crossject reports financial results and business highlights for the first six months of 2024 | 170 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
17.09. | Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 | 1 | GlobeNewswire (USA) | ||
22.08. | Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 | 1 | GlobeNewswire (USA) | ||
19.08. | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 144 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
18.07. | Crossject achieves key ZEPIZURE manufacturing milestone | 114 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
15.07. | Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
10.07. | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 134 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen | |
26.06. | Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | 158 | GlobeNewswire (Europe) | Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine... ► Artikel lesen | |
12.06. | Crossject appoints Dan Chiche, MD as Chief Medical Officer North America | 182 | GlobeNewswire (Europe) | Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes... ► Artikel lesen | |
04.06. | Crossject announces highly successful closing of its €8 million rights offering | 4 | GlobeNewswire (USA) | ||
30.05. | Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy | 1 | GlobeNewswire (USA) | ||
14.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2024 | 584 | Xetra Newsboard | Das Instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY wird ex Kapitalmassnahme gehandelt am 14.05.2024 The instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY is traded ex capital... ► Artikel lesen | |
02.05. | Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe | 1 | GlobeNewswire (USA) | ||
25.04. | Crossject reports audited financial results for 2023 | 163 | GlobeNewswire (Europe) | Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free... ► Artikel lesen | |
08.04. | XFRA 74C: WIEDERAUFNAHME/RESUMPTION | 209 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
02.04. | Crossject advances in its U.S. Strategy and reports Financial Results for 2023 | 248 | GlobeNewswire (Europe) | Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®... ► Artikel lesen | |
02.04. | XFRA 74C: AUSSETZUNG/SUSPENSION | 123 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCROSSJECT SA EO... ► Artikel lesen | |
27.02. | Crossject obtains a financing up to €12 million, in two tranches | 291 | GlobeNewswire (Europe) | Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 33,430 | -0,57 % | DAX höher, Gold weiter stark: SAP, Traton, Deutsche Börse, VW, BMW, Fresenius, Rheinmetall ... | Der DAX hat zum Wochenstart knapp unterhalb der 20.000-Punkte-Marke Luft geholt. Er ging am Ende mit einem Minus von einem Prozent auf 19.461,19 Zählern aus dem Handel. Am Donnerstag hatte der deutsche... ► Artikel lesen | |
INTUITIVE SURGICAL | 474,80 | -0,94 % | Intuitive Surgical-Aktie: Einfach nicht zu bremsen | Die Intuitive Surgical-Aktie (WKN: 888024) ist seit Monaten nicht mehr zu bremsen. Wer das Papier des OP-Roboterherstellers vor einem Jahr kaufte, darf sich heute über einen Kursgewinn von fast +80%... ► Artikel lesen | |
SERNOVA | 0,170 | -0,76 % | Sernova Aktie: Kursanstieg und positive Monatsentwicklung | Die Sernova Aktie verzeichnete am 18. Oktober 2024 einen leichten Kursanstieg von 0,48% und schloss bei 0,17635 EUR. Bemerkenswert ist die positive Monatsentwicklung mit einem Zuwachs von 12,86%. Trotz... ► Artikel lesen | |
VITA 34 | 4,480 | -0,44 % | EQS-PVR: Vita 34 AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Vita 34 AG
Vita 34 AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.10.2024 / 15:01 CET/CEST
Veröffentlichung... ► Artikel lesen | |
GERATHERM MEDICAL | 3,300 | -2,37 % | Geratherm Medical AG: Verkauf von apoplex zu attraktiven Konditionen, Kursziel erhöht; mwb research bekräftigt KAUFEN | Geratherm hat den Verkauf seines 60,55%igen Anteils an der apoplex medical technologies GmbH, die auf Schlaganfallprävention spezialisiert ist, an ein deutsch-amerikanisches Konsortium für 16,5 Mio.... ► Artikel lesen | |
ALIGN TECHNOLOGY | 192,50 | -1,43 % | Align Technology, Inc. (NASDAQ:ALGN) Shares Sold by Meridiem Investment Management Ltd. | ||
NUGEN MEDICAL DEVICES | 0,062 | -0,32 % | Kursexplosion am Montag? Zwei Weltmarktführer steigen bei NuGen Medical ein! | ||
PLUS THERAPEUTICS | 1,350 | +5,63 % | Plus Therapeutics Inc.: Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE... ► Artikel lesen | |
CARDINAL HEALTH | 103,55 | -0,43 % | What to Expect From Cardinal Health's Q1 2025 Earnings Report | ||
RESMED | 219,00 | -1,48 % | A Peek at ResMed's Future Earnings | ||
ATOSSA THERAPEUTICS | 1,398 | +0,87 % | Atossa Therapeutics, Inc.: Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer | ||
DAVITA | 152,00 | +0,56 % | What to Expect From DaVita's Next Quarterly Earnings Report | ||
MEDICLIN | 2,420 | +2,54 % | EQS-News: MEDICLIN AG: MEDICLIN berichtet solides erstes Halbjahr 2024 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresergebnis/Halbjahresbericht
MEDICLIN berichtet solides erstes Halbjahr 2024
31.07.2024 / 13:31 CET/CEST
Für den Inhalt... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem | MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences... ► Artikel lesen | |
ZIMMER BIOMET | 97,20 | +0,64 % | Zimmer Biomet-Aktie: Kurs mit wenig Bewegung (96,5425 €) | Die Wertschätzung für die Zimmer Biomet-Aktie hat sich an der Börse heute kaum geändert. Das Papier kostete zuletzt 104,99 US-Dollar. Kaum auffällig ist derzeit am Aktienmarkt der Kurs von Zimmer Biomet.... ► Artikel lesen |